Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Mazzoni

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
British Journal of Cancer|January 8, 2004
Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancerF Cappuzzo, F Mazzoni, A Gennari, et al.
Lung Cancer (Amsterdam, Netherlands)|January 2, 2018
Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsyR Minari, P Bordi, M Del Re, et al.
ESMO Open|June 15, 2024
Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO)E G Pizzutilo, A G Agostara, S Oresti, et al.
ESMO Open|March 18, 2021
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancerG L Banna, A Cortellini, D L Cortinovis, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
British Journal of Cancer|January 8, 2004
Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancerF Cappuzzo, F Mazzoni, A Gennari, et al.
Lung Cancer (Amsterdam, Netherlands)|January 2, 2018
Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsyR Minari, P Bordi, M Del Re, et al.
ESMO Open|June 15, 2024
Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO)E G Pizzutilo, A G Agostara, S Oresti, et al.
ESMO Open|March 18, 2021
The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancerG L Banna, A Cortellini, D L Cortinovis, et al.
Pageof 2